Unichem Labs gains 3 per cent on receiving USFDA tentative nod for Aripiprazole tablets

The shares of Unichem Laboratories Limited were trading higher today by 3 per cent intraday after the company announced that it has received tentative approval from United States Food & Drug Administration (USFDA) for Aripiprazole tablets in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.   

The abovementioned drug is the generic version of Abilify of Otsuka Pharmaceutical Company Limited. It is indicated for Schizophrenia, irritability associated with Autistic disorder and also, for the treatment of Tourette’s disorder.  

In a filing to BSE, the company stated that the drug will be commercialised from Unichem’s Ghaziabad Plant on receipt of full approval. 

Unichem Laboratories Limited is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics in several markets across the world.  

At 12.49 pm on Thursday, the stock of Unichem Laboratories Limited was trading at Rs 327.40, up by 3.02 per cent or 9.60 per share as against a 0.10 per cent decline in the benchmark index.  The 52-week high and 52-week low of the scrip was recorded at Rs 374.90 and Rs 173.65, respectively on BSE.